Cumberland Pharmaceuticals Inc. Revenue
Cumberland Pharmaceuticals Inc. (CPIX) reported Revenue of $166.46 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2026-08-07
- Cumberland Pharmaceuticals Inc. revenues for the quarter ending 2026-06-30 was $166.46K, a 56.29% decline year-over-year.
- Cumberland Pharmaceuticals Inc. revenues for the quarter ending 2025-06-30 was $380.80K.
- Cumberland Pharmaceuticals Inc. revenues for the quarter ending 2022-12-31 was $9.12M, a 9.66% increase year-over-year.
- Cumberland Pharmaceuticals Inc. revenues for the quarter ending 2022-09-30 was $11.41M, a 41.38% increase year-over-year.
- Cumberland Pharmaceuticals Inc. revenues for fiscal 2022 was $42.01M, a 16.75% increase from fiscal 2021.
- Cumberland Pharmaceuticals Inc. revenues for fiscal 2021 was $35.99M, a 3.89% decline from fiscal 2020.
- Cumberland Pharmaceuticals Inc. revenues for fiscal 2020 was $37.44M, a 8.88% increase from fiscal 2019.
- Cumberland Pharmaceuticals Inc. revenues for fiscal 2019 was $34.39M, a 17.19% increase from fiscal 2018.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 9 month | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $166.46K 10-Q · filed 2026-08-07 | $330.31K 10-Q · filed 2026-08-07 | ||||
| 2025-06-30 | $380.80K 10-Q · filed 2026-08-07 | $547.42K 10-Q · filed 2026-08-07 | ||||
| 2022-12-31 | $9.12M 10-K · filed 2023-03-13 | $20.54M derived: sum of 2 quarters · filed 2023-03-13 | $30.84M derived: sum of 3 quarters · filed 2023-03-13 | $42.01M 10-K · filed 2023-03-13 | ||
| 2022-09-30 | $11.41M 10-K · filed 2023-03-13 | $21.71M derived: sum of 2 quarters · filed 2023-03-13 | $32.89M derived: sum of 3 quarters · filed 2023-03-13 | $41.21M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2022-06-30 | $10.30M 10-K · filed 2023-03-13 | $21.47M derived: sum of 2 quarters · filed 2023-03-13 | $29.79M derived: sum of 3 quarters · filed 2023-03-13 | $37.87M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2022-03-31 | $11.18M 10-K · filed 2023-03-13 | $19.49M derived: sum of 2 quarters · filed 2023-03-13 | $27.57M derived: sum of 3 quarters · filed 2023-03-13 | $36.62M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2021-12-31 | $8.32M 10-K · filed 2023-03-13 | $16.39M derived: sum of 2 quarters · filed 2023-03-13 | $25.45M derived: sum of 3 quarters · filed 2023-03-13 | $35.99M 10-K · filed 2023-03-13 | ||
| 2021-09-30 | $8.07M 10-K · filed 2023-03-13 | $17.13M derived: sum of 2 quarters · filed 2023-03-13 | $27.67M derived: sum of 3 quarters · filed 2023-03-13 | $37.93M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2021-06-30 | $9.06M 10-K · filed 2023-03-13 | $19.59M derived: sum of 2 quarters · filed 2023-03-13 | $29.85M derived: sum of 3 quarters · filed 2023-03-13 | $39.10M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2021-03-31 | $10.54M 10-K · filed 2023-03-13 | $20.80M derived: sum of 2 quarters · filed 2023-03-13 | $30.05M derived: sum of 3 quarters · filed 2023-03-13 | $39.65M derived: sum of 4 quarters · filed 2023-03-13 | ||
| 2020-12-31 | $10.26M 10-K · filed 2022-03-11 | $19.51M derived: sum of 2 quarters · filed 2022-03-11 | $29.11M derived: sum of 3 quarters · filed 2022-03-11 | $37.44M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $9.25M 10-K · filed 2022-03-11 | $18.85M derived: sum of 2 quarters · filed 2022-03-11 | $27.18M derived: sum of 3 quarters · filed 2022-03-11 | $36.49M derived: sum of 4 quarters · filed 2022-03-11 | ||
| 2020-06-30 | $9.60M 10-K · filed 2022-03-11 | $17.93M derived: sum of 2 quarters · filed 2022-03-11 | $27.23M derived: sum of 3 quarters · filed 2022-03-11 | $34.17M derived: sum of 4 quarters · filed 2022-03-11 | ||
| 2020-03-31 | $8.33M 10-K · filed 2022-03-11 | $17.64M derived: sum of 2 quarters · filed 2022-03-11 | $24.57M derived: sum of 3 quarters · filed 2022-03-11 | $33.99M derived: sum of 4 quarters · filed 2022-03-11 | ||
| 2019-12-31 | $9.31M 10-K · filed 2021-03-12 | $13.68M 10-K · filed 2020-03-20 | $16.24M derived: sum of 2 quarters · filed 2021-03-12 | $25.66M derived: sum of 3 quarters · filed 2021-03-12 | $34.39M 10-K · filed 2022-03-11 | $47.53M 10-K · filed 2020-03-20 |
| 2019-09-30 | $6.94M 10-K · filed 2021-03-12 | $10.37M 10-K · filed 2020-03-20 | $16.35M derived: sum of 2 quarters · filed 2021-03-12 | $25.08M derived: sum of 3 quarters · filed 2021-03-12 | $35.57M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-06-30 | $9.42M 10-K · filed 2021-03-12 | $11.58M 10-K · filed 2020-03-20 | $18.15M derived: sum of 2 quarters · filed 2021-03-12 | $28.64M derived: sum of 3 quarters · filed 2021-03-12 | $34.49M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2019-03-31 | $8.73M 10-K · filed 2021-03-12 | $11.90M 10-K · filed 2020-03-20 | $19.22M derived: sum of 2 quarters · filed 2021-03-12 | $25.07M derived: sum of 3 quarters · filed 2021-03-12 | $32.16M derived: sum of 4 quarters · filed 2021-03-12 | |
| 2018-12-31 | $10.49M 8-K · filed 2020-12-10 | $13.50M 10-K · filed 2019-03-12 | $16.34M derived: sum of 2 quarters · filed 2020-12-10 | $23.43M derived: sum of 3 quarters · filed 2020-12-10 | $29.34M 10-K · filed 2021-03-12 | $40.74M 10-K · filed 2019-03-12 |
| 2018-09-30 | $5.85M 8-K · filed 2020-12-10 | $8.49M 10-K · filed 2019-03-12 | $12.94M derived: sum of 2 quarters · filed 2020-12-10 | $18.86M derived: sum of 3 quarters · filed 2020-12-10 | $30.51M derived: sum of 4 quarters · filed 2020-12-10 | |
| 2018-06-30 | $7.08M 8-K · filed 2020-12-10 | $10.16M 10-K · filed 2019-03-12 | $13.00M derived: sum of 2 quarters · filed 2020-12-10 | $24.65M derived: sum of 3 quarters · filed 2020-12-10 | $35.85M derived: sum of 4 quarters · filed 2020-12-10 | |
| 2018-03-31 | $5.92M 8-K · filed 2020-12-10 | $8.59M 10-K · filed 2019-03-12 | $17.57M derived: sum of 2 quarters · filed 2020-12-10 | $28.77M derived: sum of 3 quarters · filed 2020-12-10 | $37.43M derived: sum of 4 quarters · filed 2020-12-10 | |
| 2017-12-31 | $11.65M 10-K · filed 2019-03-12 | $22.85M derived: sum of 2 quarters · filed 2019-03-12 | $31.51M derived: sum of 3 quarters · filed 2019-03-12 | $26.32M 8-K · filed 2020-12-10 | $1.60M 10-K · filed 2018-03-09 | |
| 2017-09-30 | $11.20M 10-K · filed 2019-03-12 | $19.86M derived: sum of 2 quarters · filed 2019-03-12 | $29.50M derived: sum of 3 quarters · filed 2019-03-12 | |||
| 2017-06-30 | $8.67M 10-K · filed 2019-03-12 | $18.30M derived: sum of 2 quarters · filed 2019-03-12 | ||||
| 2017-03-31 | $9.64M 10-K · filed 2019-03-12 | |||||
| 2016-12-31 | $33.03M 10-K · filed 2019-03-12 | $2.00M 10-K · filed 2017-03-13 | ||||
| 2015-12-31 | $900.00K 10-K · filed 2018-03-09 | |||||
| 2014-12-31 | $600.00K 10-K · filed 2017-03-13 | |||||
| 2013-12-31 | $800.00K 10-K · filed 2016-03-14 | |||||
| 2012-12-31 | $700.00K 10-K · filed 2015-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |